NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system by French, Caitlin D. et al.
RESEARCH ARTICLE
NMR metabolomics of cerebrospinal fluid
differentiates inflammatory diseases of the
central nervous system
Caitlin D. French1, Rodney E. Willoughby2‡*, Amy Pan2, Susan J. Wong3, John F. Foley4,
L. Joseph Wheat5, Josefina Fernandez6, Rafael Encarnacion6, Joanne M. Ondrush7,
Naaz Fatteh7, Andres Paez8, Dan David9, Waleed Javaid10, Ioana G. Amzuta10, Anne
M. Neilan11, Gregory K. Robbins11, Andrew M. Brunner11, William T. Hu12, Darya
O. MishchukID13, Carolyn M. SlupskyID1,13‡*
1 Department of Nutrition, University of California, Davis, California, United States of America, 2 Department
of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, Wisconsin, United
States of America, 3 Wadsworth Center Diagnostic Immunology Laboratory, New York State Department of
Health, Albany, New York, United States of America, 4 Intermountain Healthcare, Salt Lake City, Utah,
United States of America, 5 Department of Medicine, Division of Infectious Diseases, Indiana University
School of Medicine, Indianapolis, Indiana, United States of America, 6 Hospital Infantil Robert Reid Cabral,
Santo Domingo, Distrito Nacional, Repu´blica Dominicana, 7 Inova Fairfax Hospital, Fairfax, Virginia, United
States of America, 8 Departamento de Ciencias Basicas, Universidad de la Salle, Bogota´, Colombia,
9 Rabies Lab, Kimron Veterinary Institute, Beit Dagan, Israel, 10 Department of Medicine, SUNY Upstate
Medical University, Syracuse, New York, United States of America, 11 Department of Medicine, Division of
Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America,
12 Mayo Clinic, Rochester, Minnesota, United States of America, 13 Department of Food Science and
Technology, University of California, Davis, California, United States of America
‡ These authors are joint senior authors on this work.
* rewillou@mcw.edu (REW); cslupsky@ucdavis.edu (CMS)
Abstract
Background
Myriad infectious and noninfectious causes of encephalomyelitis (EM) have similar clinical
manifestations, presenting serious challenges to diagnosis and treatment. Metabolomics of
cerebrospinal fluid (CSF) was explored as a method of differentiating among neurological
diseases causing EM using a single CSF sample.
Methodology/Principal findings
1H NMR metabolomics was applied to CSF samples from 27 patients with a laboratory-con-
firmed disease, including Lyme disease or West Nile Virus meningoencephalitis, multiple
sclerosis, rabies, or Histoplasma meningitis, and 25 controls. Cluster analyses distinguished
samples by infection status and moderately by pathogen, with shared and differentiating
metabolite patterns observed among diseases. CART analysis predicted infection status
with 100% sensitivity and 93% specificity.
Conclusions/Significance
These preliminary results suggest the potential utility of CSF metabolomics as a rapid
screening test to enhance diagnostic accuracies and improve patient outcomes.
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Author summary
Inflammation of the brain and spinal cord, known as encephalomyelitis, is a dangerous
condition that can be caused by a wide range of pathogens, such as viruses and bacteria,
and other medical conditions including autoimmunity or drug intoxications. Given the
many possible causes, it is often difficult for clinicians treating patients with encephalomy-
elitis to identify the underlying cause, which in turn determines the appropriate treatment.
Infections and other diseases causing neurological inflammation work by distinct biologi-
cal mechanisms and, consequently, can cause unique biochemical changes that can be
observed in cerebrospinal fluid of affected individuals. The researchers used a metabolo-
mics technique to measure a range of small molecules in cerebrospinal fluid and examine
biochemical differences in patients with encephalomyelitis caused by Lyme disease, West
Nile Virus, multiple sclerosis, rabies, or fungal infection. The researchers found distinct
differences in the biochemical profiles of patients whose encephalomyelitis was caused by
infections versus patients with no infection, and also identified different patterns among
the individual diseases. This study showed that metabolomics may be useful in improving
diagnosis and treatment of diseases affecting the central nervous system by enhancing
understanding of their unique effects on metabolism.
Introduction
Encephalomyelitis (EM) is a condition characterized by inflammation of the brain (encephali-
tis) and spinal cord (myelitis) that frequently causes permanent disability. There are myriad
causes of EM syndromes, which are in aggregate relatively common [1–4] and include viral,
bacterial, fungal, protozoal and prion infections, autoimmune encephalitis, intoxications, and
metabolic encephalopathies, while other EM cases have unknown causes [5]. Clinicians face
significant challenges to the rapid and accurate diagnosis and treatment of EM. Due to the rar-
ity of a definitive diagnosis, many arbovirus and other viral causes of EM, including rabies,
have limited evidence-based therapies; this may change with newer broad-spectrum antivirals
currently in clinical trials [6]. Treatment of autoimmune EM relies on corticosteroids, immu-
noglobulin, plasmapheresis, cytotoxic agents and biologicals [7, 8], which are typically contra-
indicated until infections can be excluded. Physicians are often forced to treat empirically for
infections and delay appropriate therapy for autoimmune EM, thereby worsening patient out-
comes. Moreover, for many causes of EM, no rapid diagnostic testing exists, and long delays
pending laboratory test results commonly occur before definitive treatment may be initiated;
however, superior outcomes depend on early intervention. Because there are numerous causes
of EM, including multiple infectious agents that overlap or coincide in geographic distribution,
diagnosis reliant on single-target testing is unsatisfactory as it requires quantities of tests that
are not only prohibitive in cost but also involve collecting unsafe volumes of blood or cerebro-
spinal fluid (CSF) from patients. Improved diagnostics and proxy markers of therapeutic effi-
cacy are sorely needed, especially as new treatment regimens develop.
In recent years, the development and expansion of omics technologies have presented
opportunities for discovering disease mechanisms and biomarkers of clinical significance [9–
11]. Metabolomics, the comprehensive study of small-molecule metabolites in a biofluid or tis-
sue, offers a set of clues to the biochemical workings of a body system, organ, or compartment
in a given physiological state, and has diverse applications in improving clinical diagnosis and
treatment of central nervous system (CNS) diseases and intoxications [9, 12–17].
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Metabolomics panels may also provide information about a broad spectrum of metabolic pro-
cesses involved in a disease presentation compared to traditional single-molecule assays.
Metabolites present in CSF may originate from brain metabolic processes, including interme-
diate and end products of energy metabolism, neurotransmission, inflammation and oxidative
stress responses; thus, their analysis provides insights into metabolic disturbances occurring in
CNS diseases. Among the methodological approaches taken in metabolomics studies of CSF,
1H-NMR spectroscopy carries advantages for exploratory studies both in the scope of metabo-
lite detection and its quantitative ability [18]. An additional advantage of this method is the
lack of sample consumption, given practical limitations on the volume of CSF usually available.
Further, many CNS diseases and intoxications are prevalent in countries where advanced
imaging facilities, reference laboratories and therapeutics are in short supply. Recent studies
have applied 1H NMR-based metabolomics of CSF to identify single-molecule biomarkers and
panels of metabolites associated with a range of neurological diseases such as infectious menin-
gitis [14], multiple sclerosis (MS) [13, 19, 20], Alzheimer’s [21, 22] Parkinson’s [23] and Hun-
tington’s diseases [24]. Further, this method has detected metabolic changes characterizing
different stages of disease progression in rabies and MS [12, 25]. Proxy markers of disease pro-
gression or response to therapy may also accelerate therapeutic trials while lowering their cost.
Despite significant advances in the application of NMR metabolomics in the investigation
of certain CNS diseases, such as multiple sclerosis, its potential to describe metabolic changes
occurring in many infectious neurological diseases has been less studied. Lyme disease and
West Nile Virus (WNV) are vastly under-studied in this sense, despite being the most com-
mon causes of vector-borne bacterial and viral disease, respectively, in the United States [26,
27]. Rabies is an important global zoonosis but may be underdiagnosed in some contexts due
to challenges in distinguishing it clinically from other CNS infections, such as cerebral malaria,
in areas where these are endemic [28]. Infectious diseases that invade the CNS have distinct
molecular mechanisms driving their respective pathologies [29, 30]. Further, pathogen strate-
gies to replicate while evading host immune responses can involve the disruption of a range of
endogenous metabolic processes [31], many of which have yet to be illuminated for specific
diseases; thus, explorative studies of the CSF metabolome in different disease states can pro-
vide an important window for examining potential pathogen effects on metabolism within the
CNS to lay the groundwork for future targeted diagnostics or therapeutic interventions. In the
present study CSF samples from patients representing diverse infectious and non-infectious
diseases of the CNS were analyzed by 1H NMR-spectroscopy to determine if metabolomics
profiling could distinguish diseases. We find preliminary evidence of the existence of discrimi-
nating metabolic features.
Methods
Subjects
Twenty-seven patients were diagnosed with CNS Lyme disease (n = 5, all ages, at the New
York State Department of Health), WNV meningoencephalitis (n = 5, all ages, New York State
Department of Health), Clinically Isolated Syndrome (CIS) of multiple sclerosis (MS, n = 4,
adults, Intermountain Healthcare), rabies (n = 10, all ages, at Canadian Food Inspection
Agency, Centers for Disease Control and Prevention, Kimron Veterinary Institute, National
Institutes of Health-Colombia, and New York State Department of Health), or Histoplasma
meningitis (n = 3, anonymous, at Indiana University School of Medicine). Due to ethical con-
cerns surrounding the collection of CSF from healthy individuals, healthy controls were not
available for this study. Specimens obtained as discard material from 25 anonymous children
aged 5–20 years at the Children’s Hospital of Wisconsin with no concurrent microbiological
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testing and no known encephalopathy or encephalitis served as a control group. This popula-
tion includes mostly children with cancer in remission or children being treated for pseudotu-
mor cerebri, a common non-inflammatory condition. Given patient samples were anonymous
discard material, the study was ruled to not be human research requiring informed consent by
the Children’s Hospital of Wisconsin IRB (protocol CHW 10/24). For rabies patients, for
whom multiple specimens were available, the specimen taken closest to the fourth day of hos-
pital admission was selected to minimize the influence of hypoglycemia, ketosis or renal insuf-
ficiency on presentation to the CSF metabolome. While the CSF was collected for diagnostic
purposes, precise timing is uncertain other than for rabies patients. Initially, four specimens
from patients with Histoplasma meningitis were analyzed, but one specimen had a metabolite
profile inconsistent with CSF and was excluded on the basis of containing implausible values.
Three Histoplasma specimens remained after this exclusion.
Storage and preparation of CSF samples
After collection, specimens were stored refrigerated and/or frozen until transport on dry ice to
the site of analysis, where they were stored at -80˚C until sample preparation. Once defrosted,
samples were filtered using washed Amicon Ultra-0.5 mL centrifugal filters with a cut-off of
3000 MW (Millipore, Billerica, MA) to remove lipids and proteins. When needed, filtrate vol-
ume was adjusted to 207 μL when preparing for 3mm NMR tubes or 585 μL when preparing
for 5mm NMR tubes with Type I ultrapure water from Millipore Synergy UV system (Milli-
pore, Billerica, MI). Samples were prepared for analysis by the addition of 23 μL or 65 μL of
internal standard containing approximately 5 mmol/L of DSS-d6 [3-(trimethylsilyl)-1-propa-
nesulfonic acid-d6], 0.2% NaN3, in 99.8% D2O to 207 μL or 585 μL of CSF filtrate, respectively.
The pH of each sample was adjusted to 6.8 ± 0.1 by adding small amounts of NaOH or HCl. A
180 or 600 μL aliquot was subsequently transferred to 3 mm or 5mm Bruker NMR tubes,
respectively, and stored at 4 oC until NMR acquisition (within 24 hours of sample prepara-
tion). NMR spectra were acquired as previously described [12] on a Bruker Avance 600-MHz
NMR equipped with a SampleJet autosampler using a NOESY-presaturation pulse sequence
(noesypr) at 25˚C.
Data analysis
NMR spectra were manually phased and baseline-corrected using NMR Suite v6.1 Processor
(Chenomx Inc., Edmonton, Canada), and Chenomx NMR Suite v.8.1 Profiler (Chenomx Inc.,
Edmonton, Canada) was used for quantification of metabolites. Selected NMR spectral data
from a previous rabies study in this lab [12] were compared to additional samples acquired
from Lyme, WNV, histoplasmosis and MS patients.
After correcting metabolite concentrations for dilution, data were cluster-analyzed 2 ways
for comparison using RStudio software (RStudio Version 1.0.136, Boston, MA, USA) or Stata
software (SE 14, College Station, TX, USA). First taking a data-driven approach, concentra-
tions were log10-transformed before principal component analysis (PCA) was carried out on
the covariance matrix of the centered data as an unsupervised search for trends. Alternatively,
to provide clinical context, data were normalized to z-scores using published reference ranges
in CSF (www.hmdb.ca). In instances when published norms were discrepant, those that
encompassed the range of our control population were selected. In rare instances when normal
ranges were unavailable, means and standard deviations were constructed using our 25 con-
trols. Normalization by z-scores constructed from population norms generated more skewed
data than log10-transformation across the entire spectrum of diseases and controls. Factor
analysis better tolerates skewed data than PCA and was applied to the z-scores.
Metabolomics of CNS diseases
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Based on the separation found by PCA and factor analysis, differences in metabolite con-
centrations by infection status and by individual disease diagnoses were assessed on the
untransformed data using Mann-Whitney U tests and Kruskal-Wallis tests, respectively. P-val-
ues were adjusted for multiple comparisons using false discovery rates. Homogeneity of vari-
ance between groups was tested using the Levene test to inform interpretation of the rank sum
test results. For metabolites with significant differences by Kruskal-Wallis testing, Dunn’s mul-
tiple comparisons tests were performed between each pair of groups to determine which dis-
eases were different from each other. For these tests, p-values were Bonferroni-adjusted within
the 15 multiple comparisons carried out for each metabolite. After adjustment, p-values of less
than 0.05 were considered significant. Cliff’s Delta statistics [32] were calculated to assess the
degree of overlap in metabolite concentrations by infection status and between diseases that
were found to have significant differences by the Dunn’s test.
Untransformed data were also analyzed by predictive analysis [33, 34]. Classification and
regression trees (CART) and Random Forests were performed using Salford Predictive Mod-
eler software suite CART and suite Random Forests (Salford Systems, San Diego, CA, USA).
For CART, parent node and terminal node were 10 and 5, respectively. 10% leave-out samples
were used for cross-validation. Random Forests are collections of decision trees, and each tree
was grown on a random (~2/3) subsample of the data. The remaining data were used to deter-
mine the performance of the trees. The number of trees to build was 1000. The number of pre-
dictors considered for each node was the square root of the number of potential predictors,
and the parent node minimum cases was 2. The variable importance was assessed using the
GINI method. Target variable and predictors were the same as for CART.
Results
CSF samples obtained from 25 controls and 27 patients with different neurological diseases
were analyzed by 1H-NMR spectroscopy. Table 1 summarizes clinical characteristics of
patients included in this study. A total of 57 compounds were identified and quantified in CSF
samples; rabies spectra from a prior study [12] were repeat-profiled. Quantification for 13
metabolites present at very low concentrations in a majority of samples was considered not to
be exact (S1 and S2 Tables) but still useful in detecting differences between groups. To further
minimize the reversible behavioral effects of starvation and dehydration in the analysis nor-
malizing by z-scores, we excluded 3 ketone bodies (3-hydroxybutyrate, acetoacetate, and ace-
tone) and creatinine from the dataset.
Metabolite profiles by infection status
A major clinical challenge is determining whether infection exists as a contraindication to
immunosuppression. Unsupervised PCA was performed on metabolite data from patients
Table 1. Patient characteristics.
Diagnosis (n) Age, median (range) Sex, female count (%) Location
Rabies (10) 8 (4–63) 2 (20) Global1
West Nile Virus (5) 65 (53–83) 2 (40) USA
Lyme Disease (5) 19 (7–55) 1 (20) USA
Fungal (3) unknown unknown USA
Multiple Sclerosis (4) 31 (22–49) 3 (75) USA
1Samples came from USA, Colombia, Dominican Republic, and Equatorial Guinea
https://doi.org/10.1371/journal.pntd.0007045.t001
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diagnosed with a neurological disease and controls. Six compounds (acetaminophen, ethanol,
ethylene glycol, glycerol, propylene glycol, and valproate) of likely exogenous origin were
excluded from cluster analysis models. The first two principal components (PC) in this model
accounted for 37.8 percent of the variation in metabolite concentrations. Prominent overlap
was apparent between controls and MS, which separated distinctly from infectious diseases
along PC 1 (Fig 1). In a scores plot of the first two components, PC 2 identified an apparent
outlier in the WNV group, which upon closer examination was observed to have extremely
low levels of citrate, lactate, and amino acids coupled with markedly high glutamate, pyruvate,
acetate and 2-oxoglutarate compared to the rest of the samples. Since the general patterns gen-
erated by PCA did not change when this individual was removed from the dataset, the results
shown in Fig 1 reflect this exclusion in order to better visualize clusters in the data.
Fig 1. Principal component analysis of 1H-NMR CSF metabolomic data comparing infectious or autoimmune disease or
controls. Axes represent principal component (PC) scores. The percent of the variation explained by each component is given in
parentheses. Green circles represent control patient samples, red circles represent multiple sclerosis patient samples, and blue circles
represent infectious disease patient samples. Normal data ellipses are shown for each group. Vectors represent loadings of select
metabolites with PC1 and PC2, as drawn in the Gabriel’s biplot. Groups of vectors that point in similar directions tend to change
together. One extreme observation was excluded to better visualize the data.
https://doi.org/10.1371/journal.pntd.0007045.g001
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When overlaid with loadings vectors, the scores plot of the first two PCs revealed two pat-
terns of metabolites among infectious diseases, one characterized by higher levels of ketone
bodies and the other by higher levels of pyruvate, glutamate, 2-oxoglutarate, carnitine, and gly-
cine (Fig 1). Pearson correlation coefficients reflect moderate to high correlation among the
metabolites in each pattern, with correlation coefficients ranging from 0.77 to 0.93 among
ketone bodies and from 0.23 to 0.58 among metabolites in the second pattern. In contrast,
metabolites including acetate, isobutyrate, myo-inositol, threonine, and glutamine appeared to
characterize controls and MS using loadings vectors.
The contribution of ketone bodies to the PCA analysis prompted a second, clinically appli-
cable analysis using z-scores of normal human values for each metabolite while excluding the
potentially non-specific markers of dehydration and starvation, which yielded similar results.
Unsupervised factor analysis discriminated CNS disease from controls, with 2 factors account-
ing for 35.6 percent of the variation. The WNV sample that appeared as an outlier by PCA was
not influential in this analysis. Factor analysis excluding ketones and creatinine did not dis-
criminate infections from normal as well as did the PCA analysis.
Given the graphical separation by infection status shown by PCA and factor analysis,
Mann-Whitney U tests were performed to test for differences in metabolite concentrations
between patients with an infectious CNS disease and those with no CNS infection (MS and
controls). All metabolites were included. These results are summarized in Table 2. After cor-
recting for multiple comparisons, significant univariate differences were detected in the con-
centrations of 29 compounds; these included several metabolites that appeared to drive
separation in the PCA (ketones, pyruvate, carnitine, and glycine). Median concentrations of
glutamate and 2-oxoglutarate were significantly higher in infectious diseases than patients
with no infectious disease, and there was a trend towards higher citrate concentrations in the
infectious disease group (p = 0.07). Also, in agreement with the PCA results, median concen-
trations of isobutyrate, fructose, N-acetylneuraminate, and serine were higher in the noninfec-
tious disease group, and acetate exhibited different distributions between the groups. In a
similar univariate analysis on z-scores for 43 variables, nine metabolites were identified
(Table 2, among bolded metabolites), all of which were also identified using the previous
method.
Metabolite profiles by CNS disease
While CNS infections overlap as a syndrome, they are caused by viruses, bacteria, fungi, proto-
zoa and prions that require different therapies. We therefore evaluated PCA discrimination
within CNS diseases without the influence of controls. In the resulting model, PC1 and PC2
cumulatively accounted for 38.9 percent of the variation, and when loadings vectors were over-
laid with PC scores, the resulting Gabriel’s biplot revealed the most important metabolites to
be ketone bodies, glutamine, glutamate, and threonine. In a scores plot of the first two PCs,
moderate separation by disease diagnosis pointed to differential as well as overlapping meta-
bolic patterns among diseases (Fig 2), which were further dissected in additional analyses and
are summarized in Tables 3 and 4. After removing ketones and creatinine, factor analysis of z-
scores did not separate cleanly between disease groups.
After correcting for multiple comparisons, Kruskal-Wallis tests on untransformed data
detected significant differences among diseases and controls in the concentrations of 31
metabolites. Metabolites and diseases for which concentrations were significantly different
from control samples according to Dunn’s multiple comparisons tests are shown in Table 4. In
particular, the CSF of WNV patients had markedly higher concentrations of pyruvate
(p = 0.0008) and formate (p = 0.0005), and Lyme disease and WNV patients shared higher
Metabolomics of CNS diseases
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levels of formate and glycine compared to controls. Rabies patients had significantly different
concentrations of energy-related metabolites including ketone bodies, lactate and 2-hydroxy-
butyrate, some of which were also elevated in WNV but not in histoplasmosis or Lyme disease.
Predictive analyses by infection status and CNS disease
CART analysis differentiated infection status with 100% sensitivity and 93% specificity
(Table 5). High pyroglutamate alone discriminated WNV, Lyme and histoplasmosis from con-
trols. MS or rabies could be identified from controls with 100% sensitivity and 76% specificity
by high 2-hydroxybutyrate or low 2-hydroxybutyrate and high carnitine. Random Forest anal-
yses confirmed the importance of the majority of metabolites identified by CART.
Table 2. Differences in cerebrospinal fluid metabolite concentrations between patients with an infectious disease (Hisotoplasma, Lyme, rabies, West Nile virus) and
non-infectious conditions (multiple sclerosis, controls)a.
Metabolite Potential Pathway(s) Involved Effect Sizeb P-valuec
Betaine 1-carbon metabolism/ cell volume/choline oxidation 0.58 0.0022
Formated 1-carbon metabolism/acetate synthesis 0.68 <0.0001
Glycinee 1-carbon metabolism/glutathione synthesis/excitotoxicity 0.62 0.0011
Cholinee 1-carbon metabolism/lipid turnover 0.45 0.0166
Serine 1-carbon metabolism/protein catabolism -0.52 0.0059
Pyroglutamatee Amino acid/glutathione metabolism 0.80 <0.0001
N-Acetylneuraminate Amino sugar metabolism/innate immunity -0.48 0.0117
Fructose Carbohydrate -0.52 0.0059
Acetatee Carbohydrate and fatty acid metabolism -0.44 0.0182
2-Oxoglutarate Cell volume/TCA cycle/amino acid metabolism 0.39 0.0387
N-Acetylaspartate Cell volume/TCA cycle/myelin synthesis 0.37 0.0499
Glutamate Cell volume/TCA cycle/neurotransmitter 0.82 <0.0001
Methanolf Drug metabolite; microbial metabolism -0.46 0.0140
Pyruvated Energy metabolism 0.55 0.0007
Lactatee Energy metabolism 0.21 0.0059
Carnitined Fatty acid catabolism 0.54 0.0009
2-Hydroxybutyratee Glutathione synthesis/energy metabolism 0.65 0.0007
Acetonee Ketone bodies 0.70 0.0002
3-Hydroxybutyratee Ketone bodies 0.59 0.0022
Acetoacetatee Ketone bodies 0.51 0.0070
Isobutyrate Microbial metabolism -0.41 0.0292
Isopropanol Microbial/ketone metabolism 0.76 0.0001
2-Oxoisocaproated Organic acid 0.39 0.0170
Urea Protein catabolism 0.38 0.0444
Phenylalanine Protein catabolism 0.37 0.0494
Quinolinated Tryptophan metabolism/excitotoxicity 0.51 0.0016
Ornithined Urea cycle 0.36 0.0258
3-Hydroxyisobutyrated Valine metabolism 0.40 0.0150
aMetabolites identified by factor analysis using z-score normalization are shown in bold. bCliff’s Delta d statistic. Positive values indicate increased concentrations in
patients with an infection compared to no infectious disease.
cResult of Mann-Whitney U test.
dDifference in median concentrations confirmed after log transformation of the data improved homoscedasticity. P-value reported corresponds to test performed on
log-transformed data.
eAssumption of equal variances not met. P-value reported corresponds to test performed on log-transformed data.
fTentatively assigned.
https://doi.org/10.1371/journal.pntd.0007045.t002
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Fig 2. Principal component analysis of 1H-NMR CSF metabolomic data comparing neurological diseases. Samples
were collected from patients with multiple sclerosis (MS, represented in green), fungal infection (red), Lyme disease
(blue), West Nile virus (WNV, orange), and rabies (purple). Normal data ellipses are shown for each group. Axes
represent principal component (PC) scores. The percent of the variation explained by each component is given in
parentheses. Vectors represent loadings of select metabolites with PC1 and PC2, as drawn in the Gabriel’s biplot. Groups
of vectors that point in similar directions tend to change together. One extreme observation was excluded.
https://doi.org/10.1371/journal.pntd.0007045.g002
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Discussion
NMR metabolomics distinguished infectious and inflammatory disorders using laboratory-
confirmed samples of 5 disorders using 2 approaches to normalization of the data, and 2 unsu-
pervised cluster analytical approaches. CART decision analysis easily differentiated bacterial
(Lyme), fungal (Histoplasma) and viral (WNV) causes of encephalomyelitis from controls.
Decision analysis also differentiated rabies and the prodromal form of MS from controls,
while separation by cluster analyses was incomplete between MS and controls. Notably, the
greatest source of variation in metabolomics data found by PCA was the presence or absence
of an infectious pathogen. If replicated, this finding is of paramount clinical impact because
treatments for infections require almost polar opposite therapeutics than those for autoim-
mune diseases. There was also substantial agreement in the identification of influential metab-
olites between different approaches to data normalization and reduction and predictive
approaches, including CART and random forest analysis. Metabolites driving separation in
PCA (pyruvate, glutamate, quinolinate, 2-oxoglutarate, carnitine, and glycine) potentially
Table 3. Metabolites with differences in cerebrospinal fluid concentrations between two or more disease groupsa.
Metabolite Potential Pathway(s) Involved Adjusted P-value
Formateb 1-carbon metabolism/acetate synthesis 0.0003
Glycinec 1-carbon metabolism/glutathione synthesis/excitotoxicity 0.005
Choline 1-carbon metabolism/lipid turnover 0.043
Serine 1-carbon metabolism/protein catabolism 0.038
Glutaminec Amino acid metabolism 0.023
Pyroglutamateb Amino acid/glutathione metabolism 0.0003
N-Acetylneuraminate Amino sugar metabolism/innate immunity 0.013
Betaine Cell volume/1-carbon metabolism/choline oxidation 0.008
NAAG Cell volume/neurotransmitter 0.021
2-Oxoglutarate Cell volume/TCA cycle/amino acid metabolism 0.030
Glutamate Cell volume/TCA cycle/neurotransmitter 0.0003
Methanold Drug metabolite; microbial metabolism 0.043
Glucoseb Energy metabolism 0.002
Lactatec Energy metabolism 0.039
Pyruvateb Energy metabolism 0.003
Carnitine Fatty acid catabolism 0.002
2-Hydroxybutyrateb Glutathione synthesis/energy metabolism 0.002
3-Hydroxybutyrateb Ketone bodies 0.031
Acetoacetate Ketone bodies 0.009
Acetonec Ketone bodies 0.002
Dimethyl sulfone Microbial metabolism 0.011
Isopropanol Microbial/ketone metabolism 0.002
2-Hydroxyisovalerate Organic acid 0.018
Phenylalanine Protein catabolism 0.033
Quinolinate Tryptophan metabolism/excitotoxicity 0.018
3-Hydroxyisobutyrate Valine metabolism 0.010
Acetamide 0.002
Abbreviation: NAAG, N-Acetylaspartylglutamic acid. aKruskal-Wallis test for nonparametric one-way analysis of variance, adjusted for multiple tests using the false
discovery rate correction.
bDifference in median concentrations confirmed after log transformation of the data improved homoscedasticity. cAssumption of equal variances not met.
dTentatively assigned.
https://doi.org/10.1371/journal.pntd.0007045.t003
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Table 4. Differences in cerebrospinal fluid metabolite concentrations compared to controls, by disease.
Cliff’s Delta Statistica
Metabolite Potential Pathway(s) Rabies West Nile Virus Lyme Disease Fungal
3-hydroxybutyrateb Ketone bodies 0.64�
3-hydroxyisobutyrate Valine metabolism 0.62�
Acetoacetate Ketone bodies 0.75�
Lactatec Energy metabolism 0.62�
Isopropanol Microbial/ketone metabolism 0.83��d 0.89��
Glutamate Cell volume/TCA cycle/neurotransmitter 0.67d 0.96�d 0.83�
2-hydroxybutyrateb Glutathione synthesis/energy metabolism 0.89�� 0.87��
Acetonec Ketone bodies 0.61� 0.92��
N-Acetylneuraminate Amino sugar metabolism/innate immunity -0.93��
Pyruvateb Energy metabolism 1.00���
Betaine Cell volume/1-carbon metabolism/choline oxidation 1.00��
2-hydroxyisovalerate Organic acid 0.81�
Carnitine Fatty acid catabolism 0.98�� 0.95�
Pyroglutamateb Amino acid/glutathione metabolism 1.00�� 1.00�� 1.00�
Glycinec 1-carbon metabolism/glutathione synthesis/excitotoxicity 0.98�� 0.97�
Quinolinate Tryptophan metabolism/excitotoxicity 0.90� 0.97�
Formateb 1-carbon metabolism/acetate synthesis 0.98��� 0.98��
Glutaminec Amino acid metabolism -1.00�
aEstimate of effect size as degree of non-overlap in concentration distributions, where 0 indicates complete overlap and 1 or -1 indicates complete non-overlap.
Significance level is indicated by Dunn’s multiple comparisons test. bDifference confirmed after log transformation of the data improved homoscedasticity. Significance
level reflects test result on log-transformed data. cAssumption of equal variances not met. dResult when one extreme value was removed as a conservative measure,
which attenuated the effect size and p-value. �P<0.05
��P<0.01
���P<0.001
https://doi.org/10.1371/journal.pntd.0007045.t004
Table 5. Predictive analyses using classification and regression trees (CART) and random forest importance scores.
Prediction Predictor(s) Sensitivity Specificity Random Forest Relative Importance
Scorea
Encephalomyelitis vs controls Pyroglutamate >35.44 μM
or
Pyroglutamate �35.44 μM &
NAAG <1.04 μM
96.3% 96% Pyroglutamate 99.94
NAAG 46.65
Infection vs not (MS + controls) Pyroglutamate >35.44 μM
or
Pyroglutamate �35.44 μM &
Glucose > 3.92 mM
100% 93% Pyroglutamate 100
Glucose 7.96
WNV, Lyme, histoplasmosis vs controls Pyroglutamate >35.67 μM 100% 100% Pyroglutamate 100.00
Rabies, MS vs controls 2-hydroxybutyrate > 41.61 μM
or
2-hydroxybutyrate�41.61 μM & Carnitine
>2.15 μM
100% 76% 2-hydroxybutyrate 96.65
Carnitine 20.33
WNV, Lyme, histoplasmosis vs rabies,
MS
Acetamide > 1.98 μM
Betaine > 3.33 μM
84.6% 100% Acetamide 100
Betaine 34.53
Abbreviations: NAAG, N-Acetylaspartylglutamic acid; MS, Multiple Sclerosis; WNV, West Nile Virus
aGINI method was used, 100 representing the highest score
https://doi.org/10.1371/journal.pntd.0007045.t005
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suggest alterations in energy metabolism, excitotoxicity and antioxidant response. Patterns of
these metabolites were not uniform. Rather, overlapping as well as distinguishing metabolic
features were seen, highlighting the potential utility of measuring a suite of metabolites rather
than searching for individual metabolic biomarkers for diseases, which may not exist. Overlap
of profiles makes strong clinical sense given that EM syndromes overlap in signs and symp-
toms. The overlap also supports a clinical rationale for syndromic metabolic therapies across a
range of infectious or autoimmune causes of EM. Distinguishing features provide promise of
rapid, relatively specific diagnoses that enable prompt pathogen or process-directed therapies.
Significant differences by disease group were found in the CSF concentrations of several
metabolites known to be involved in the synthesis of the antioxidant glutathione (GSH) and
related pathways, including glycine, formate, pyroglutamate, and 2-hydroxybutyrate. The
transsulfuration pathway links the methylation cycle of one carbon metabolism to GSH syn-
thesis and produces 2-hydroxybutyrate as a secondary byproduct during the conversion of
cystathionine to cysteine [35, 36]. Formate, an endogenous and bacterial metabolite that along
with glycine was found at significantly higher levels in WNV and Lyme disease patients com-
pared to controls in this study, is formed as a byproduct in several pathways including the
tryptophan kynurenine pathway [37], pterin metabolism [38] and protein demethylation (fol-
lowing hypermethylation by S-adenosyl-L-methionine [39]), while it is also consumed in the
folate cycle during the conversion of tetrahydrofolate (THF) to 10-formyl-THF [40]. An end
product of purine catabolism, neopterin, has been found to be elevated in patients with rabies
[41], Lyme disease, and other neuroinfections, while remaining low in MS and other neuroin-
flammatory conditions [42]. Pyroglutamate, which converts to glutamate before being incor-
porated into GSH and also activates amino acid transport systems at the blood brain barrier
[43], was higher in histoplasmosis, Lyme disease and WNV and was an important predictor
distinguishing these conditions from control samples. Given individual metabolites can partic-
ipate in a number of biochemical pathways, further studies are required to parse out the mech-
anisms at play in the diseases studied here. A likely interpretation is that infection or
inflammation in the CNS is associated with redox imbalances including glutathione metabo-
lism and NADH/NAD+ ratios. It is of particular interest that these metabolites may profile
mechanisms leading to insulin resistance and vascular disease [36], given that low dose insulin
therapy was added to the Milwaukee protocol, version 4, with statistical improvements in sur-
vival [44].
Our analytical design sought to minimize the effects of starvation/ketosis and dehydration/
uremia on the metabolic profile of rabies by prioritizing rabies samples taken four days after
admission. Nevertheless, PCA analysis identified the importance of ketone bodies in identify-
ing rabies. Factor analysis that deliberately excluded primary ketones, urea and creatinine
from analysis still identified isopropanol and methanol (Table 3), both downstream metabo-
lites of ketones, as discriminators of rabies. RF and CART analyses also identified ketones and
carnitine (fatty acid oxidation) as predictors of rabies but not other infections (Table 5).
Despite our experimental design, CNS ketosis may be a valid indicator of rabies encephalitis.
This study was originally intended to further explore the specificity of NMR metabolomics
for the diagnosis of rabies, which is often confused with Guillain-Barre syndrome, acute psy-
chosis and N-methyl-D-aspartate receptor (NMDAR) encephalitis and currently requires mul-
tiple tests for diagnosis at remote reference laboratories. Our findings suggest that the utility of
the approach may instead lie in excluding competing diagnoses, many of which are more treat-
able. NMR metabolomics performed on a par with current rabies diagnostics (100% sensitivity,
76% specificity) and is likely complementary (particularly after 5 days). When restricted to the
first week of hospitalization with rabies (when most patients die), NMR metabolomics did not
perform as well as for other infections; gene expression studies of rabies CSF and detection of
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rabies-specific antibodies also performed poorly in the first week. Rabies can clearly be delin-
eated from controls by NMR at later time points, and NMR of CSF also measures recovery
[12]. The promise of an NMR metabolomics profile as a proxy marker for therapeutic response
would be welcome for rabies, WNV, NMDAR encephalitis or acute disseminated encephalo-
myelitis for which efficacious treatments remain undefined.
This study is exploratory and is limited by the number of samples available for CNS diseases
of rare incidence. The possibility of confounding effects of age, sex, disease stage, or other
acute variations in metabolic processes should be considered in interpreting these results. Our
control group was aged 5–20 years, while ages in the disease group ranged from 4 to 83 years.
However, we confirmed that the distribution of metabolites of our controls overlapped with
adult norms reported by the international Human Metabolomics Database (www.hmdb.ca).
Further, clear inter-disease differences within groups of adult diseases (MS, WNV) were evi-
dent in PCA (Fig 2), suggesting disease was much more influential in driving variation than
was age. Sensitivity analyses in rabies in a larger dataset [12] did not identify meaningful age
differences, although we cannot exclude the possibility that this might occur for other inflam-
matory diseases of the CNS. Another potential source of confounding is the timing of sample
collection, which was not precisely known for samples other than rabies. All forms of encepha-
litis are treated empirically upon hospitalization, so early diagnostic samples such as those ana-
lyzed here may reflect early empirical therapies that often overlap (e.g., rehydration, provision
of glucose, use of antibacterials, sedation) but may also differ between diseases. Our choice of
rabies samples centered on the fourth day of hospitalization was intended to minimize effects
of dehydration and malnutrition, but may have biased rabies samples toward normality.
Finally, differences in some metabolites should be interpreted with caution, since low concen-
trations in some specimens precluded exact quantification (carnitine and glycine), which may
have artificially led to statistical differences. Other metabolites (glutamine and pyroglutamate)
are potentially affected by protein removal [45], although this has not been shown in CSF.
This study provides justification for further analysis of samples from these and other causes
of encephalomyelitis. Several prominent and as of yet unidentified peaks observed in the spec-
tra of some patients may indicate the presence of important metabolites involved in disease
pathogenesis that have not yet been elucidated. While further studies with larger sample sizes
will be needed to determine the clinical utility of NMR in the diagnosis of EM, NMR or other
‘omics technologies may in the future serve as a rapid initial screening test that would allow
medical practitioners to initiate treatment with antivirals or biological immune modifiers,
while patient samples can then be triaged to appropriate reference laboratories for confirma-
tion without delaying treatment. Rabies and many arbovirus reference laboratories require
specialized containment facilities, immunization of laboratory workers, and highly trained
personnel who perform subjective assays such as immunofluorescence. Reference laboratories
for rabies, arboviruses, bacteria and fungi are often dispersed geographically, leading to sub-
stantial requirements in volume, delay, and cost for diagnosis of encephalomyelitis when all
are considered. NMR and MS instruments, on the other hand, exist at most research universi-
ties, i.e. at a state or provincial rather than national level. NMR analytical procedures are easily
standardized and permit detection of multiple diseases using a single experiment, as illustrated
here. NMR spectra can be transmitted electronically for analysis, which can be automated
[46]. Decision analytical approaches such as CART and RF offer diagnostic flow charts that are
easily implemented once validated, with quantifiable diagnostic probabilities. Considering cur-
rent challenges, its relative ease of use makes NMR metabolomics of CSF a potentially impor-
tant tool for emergent diseases and distinguishing between autoimmune and infectious EM.
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